Abiopharma

AdaptHealth Corp. Announces Upgraded S&P Global Issue-Level Rating on Senior Unsecured Debt

PRGO CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit On Behalf Of Perrigo Company plc Shareholders

Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy

Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London

Henlius e Organon annunciano lapprovazione, da parte della US FDA, di POHERDY® (pertuzumab-dpzb), il primo biosimilare di PERJETA (pertuzumab) negli Stati Uniti

AirSculpt Technologies Appoints Mike Doyle as Non-Executive Chairman of the Board

Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring

OmniAb - OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors

OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors

OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors